AI CT MRI Result Comparison: Oncology Monitoring & Progression

How does a radiologist objectively measure a 2mm change in a necrotic tumor core across three different ct scanners over eighteen months? The human eye is remarkable. But it fails at the grueling, longitudinal consistency needed to separate true disease progression from a slight change in slice thickness or a pesky reconstruction artifact. This gets even harder when you're jumping between modalities, like comparing an initial MRI to a follow-up CT where signal intensities and Hounsfield Units (HU) don't align in any linear way. I’ve deployed these models across hospital networks in Southeast Asia, and I’ve learned that the primary barrier isn't just spotting the lesion. It is the spatial and temporal normalization of data that originated from a dozen different manufacturers.

The technical weight of comparing 'prior' and 'current' studies usually forces a reliance on RECIST 1.1 measurements. They are fine, but they are 2D. They are limited. When we were validating the Fractify engine for volumetric analysis, we saw 2D measurements frequently miss eccentric growth patterns that 3D voxel-based AI identifies immediately. Fractify detects brain MRI tumors at 97.9% accuracy, providing a level of precision that manual annotation rarely matches in high-throughput environments.



PACS integration lets this happen in the background before the radiologist even opens the study. Is a 3% increase in volume a clinical progression or just the result of a different reconstruction kernel? Doctors ask this every single day. It’s the classic friction point where raw model accuracy hits the messy reality of clinical utility, and if an AI spits out a result without explaining the underlying registration logic, that trust evaporates instantly. We utilize Grad-CAM heatmaps to provide visual evidence of why the model flagged a specific area as progressive disease (PD) versus stable disease (SD).

Managing oncology progression requires a deep understanding of multi-modal data. While CT remains the gold standard for lung and bone imaging—where Fractify maintains a 97.7% bone fracture detection accuracy—MRI provides superior soft-tissue contrast for neuro-oncology and pelvic malignancies. AI systems must normalize these disparate data streams into a unified timeline. This involves complex HL7/FHIR integration to pull relevant clinical history and ensure that the AI is 'aware' of the patient’s treatment phase, such as post-surgical changes versus new metastatic deposits. My take: The most valuable AI doesn't just find the tumor; it manages the historical context of the patient's entire imaging record.

Data diversity is the real killer.

Building a neural network is the easy part. Making it work on a 1.5T scan from an old machine in a rural clinic when it was trained on high-res 3T MRI is where things usually break. Fractify uses robust data augmentation and domain adaptation techniques to ensure that the 97.9% accuracy we claim remains consistent regardless of the hardware used. Radiologists who've integrated Fractify into their PACS workflow tell me that the 'prior-study comparison' feature is the single most significant time-saver, reducing the cognitive load of searching for and aligning historical folders by nearly 40% per case.

Metric Category	Manual Radiologist Review	Fractify AI Integration
Average Comparison Time	12-15 Minutes	< 2 Minutes
tumor detection Accuracy	~85-91% (Variable)	97.9% (Brain MRI)
Volumetric Consistency	High Inter-observer variance	99.2% Reproducibility
Prior Study Alignment	Manual Side-by-Side	Automated Voxel Mapping

Deployment is a constant tug-of-war between model depth and latency. A clinician cannot wait 300 seconds for a comparison to load. We have optimized our pipelines to deliver results in under 30 seconds by leveraging edge computing within the hospital's secure network, ensuring that RBAC (Role-Based Access Control) is strictly maintained to protect patient privacy. This is critical when dealing with sensitive oncology data. I'll be honest — I haven't seen enough data to say definitively whether AI can fully replace RECIST 1.1 manual validation in Phase I clinical trials just yet, but for routine clinical monitoring, the shift is already happening.

Fractify classifies 6 intracranial hemorrhage subtypes and detects 18+ pathologies in chest x-rays, including critical conditions like Tension Pneumothorax and Aortic Dissection. However, a specific scenario where I would NOT recommend relying solely on AI is during the immediate post-operative window (0-48 hours), where surgical artifacts, gelfoam, and acute edema create 'noise' that can still confuse even the most advanced convolutional neural networks. Personally, I'd argue human oversight remains non-negotiable in those cases.



Maintaining clinical trust requires transparency. We adhere to DICOM standards for all metadata handling, ensuring that the AI’s findings are stored as Structured Reports (SR) or Secondary Capture (SC) objects that any standard viewer can display. This interoperability is what allows Fractify to function as a seamless layer over existing hospital infrastructure. As reported in publications like European Radiology, the transition toward quantitative imaging is the only way to manage the increasing volume of oncology follow-ups in an aging global population.



The future of oncology monitoring is not just 'seeing' better, but 'measuring' better. By removing the subjectivity of manual measurement, Fractify allows oncologists to make treatment decisions—such as switching chemotherapy agents or recommending salvage radiation—with a higher degree of confidence. We continue to refine our models to handle increasingly complex cases, but the core mission remains: transforming pixels into actionable clinical intelligence.

How does Fractify compare CT and MRI scans from different years?

Fractify utilizes deformable image registration to align voxel coordinates across timeframes. The AI normalizes different slice thicknesses and reconstruction kernels to ensure that the volume of a tumor in a 2022 MRI is directly comparable to a 2024 CT scan, minimizing errors from equipment variability.

What is the validated accuracy for brain tumor detection in Fractify?

Fractify achieves a 97.9% accuracy rate for detecting and segmenting brain tumors in MRI studies. This performance has been validated against expert neuroradiologist ground truth, ensuring that even subtle progression or new satellite lesions are identified during longitudinal monitoring.

Does this AI integrate with existing hospital PACS and RIS?

Yes, Fractify is designed for seamless integration using DICOM, HL7, and FHIR standards. It functions as a background service that processes imaging data and returns results directly to your existing PACS workstation, requiring no change to the clinician’s primary interface.

Can Fractify detect progression in non-solid tumors?

While Fractify excels at solid tumor volumetry, its current primary validation is for lesions with measurable mass. It utilizes advanced segmentation to track the density and volume changes in various oncology presentations, though extremely diffuse infiltrative patterns may still require specialist oversight.

How does the system handle patient movement between scans?

The system employs non-rigid registration algorithms that compensate for anatomical shifts and patient positioning differences. By mapping the anatomy onto a standardized atlas, the AI ensures that longitudinal comparisons are spatially accurate despite variations in how the patient was scanned.

What are the time savings for a typical oncology follow-up report?

Integrating Fractify reduces the time spent on manual tumor measurement and prior-study comparison by up to 40%. Instead of manual 2D calipers, the radiologist reviews an automated volumetric delta report, allowing for faster throughput without sacrificing diagnostic depth.

Is the AI's decision-making process transparent to the radiologist?

Transparency is maintained through Grad-CAM heatmaps and structured reporting. The AI provides a visual 'map' of the areas it has identified as progressive, allowing the radiologist to verify the logic behind every segmentation and measurement before signing off the report.

What bone-related pathologies can the AI detect alongside oncology?

Fractify maintains a 97.7% accuracy for bone fracture detection and can identify 18+ pathologies in chest X-rays. In oncology contexts, this is particularly useful for identifying blastic or lytic bone metastases that may occur alongside primary tumor progression.